Wave Life Sciences Ltd Cash Flow Conversion Efficiency
Wave Life Sciences Ltd cash flow conversion efficiency. Based on the latest financial reports, Wave Life Sciences Ltd (WVE) has a cash flow conversion efficiency ratio of -0.116x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-59.55 Million) by net assets ($511.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Wave Life Sciences Ltd (2013–2025)
Cash flow conversion efficiency of Wave Life Sciences Ltd from 2013 to 2025. This chart illustrates how Wave Life Sciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Wave Life Sciences Ltd (WVE) stock price for real-time trading data and today's change.
Wave Life Sciences Ltd Cash Flow Conversion Ratio Explained
Wave Life Sciences Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Wave Life Sciences Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Wave Life Sciences Ltd ranked by their cash flow conversion efficiency. Also see Wave Life Sciences Ltd market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Founder Motor Co Ltd
SHE:002196
|
0.024x |
|
Global Top E Commerce Co Ltd
SHE:002640
|
-0.326x |
|
Gujarat Ambuja Exports Limited
NSE:GAEL
|
0.038x |
|
Shentong Technology Group Co Ltd
SHG:605228
|
0.058x |
|
Southern California Bancorp
NASDAQ:BCAL
|
0.025x |
|
First Watch Restaurant Group Inc
NASDAQ:FWRG
|
0.043x |
|
Zhejiang Dehong Automotive
SHG:603701
|
-0.014x |
|
SeAH Bestee
KO:001430
|
0.026x |
Annual Cash Flow Conversion Efficiency for Wave Life Sciences Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Wave Life Sciences Ltd from 2013 to 2025. Review WVE cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $526.23 Million | $-187.49 Million | -0.356x | +50.57% |
| 2024-12-31 | $209.51 Million | $-151.03 Million | -0.721x | -47.02% |
| 2023-12-31 | $39.63 Million | $-19.43 Million | -0.490x | -117.30% |
| 2022-12-31 | $-45.09 Million | $-127.78 Million | 2.834x | +203.48% |
| 2021-12-31 | $32.50 Million | $-88.99 Million | -2.738x | -114.04% |
| 2020-12-31 | $90.65 Million | $-115.98 Million | -1.279x | +51.33% |
| 2019-12-31 | $71.61 Million | $-188.23 Million | -2.629x | -743.37% |
| 2018-12-31 | $73.35 Million | $-22.86 Million | -0.312x | +47.92% |
| 2017-12-31 | $139.81 Million | $-83.67 Million | -0.598x | -153.23% |
| 2016-12-31 | $134.86 Million | $-31.87 Million | -0.236x | -189.57% |
| 2015-12-31 | $153.49 Million | $-12.53 Million | -0.082x | +96.26% |
| 2014-12-31 | $2.03 Million | $-4.43 Million | -2.184x | -577.29% |
| 2013-12-31 | $-7.76 Million | $-3.55 Million | 0.457x | -- |
About Wave Life Sciences Ltd
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent diso… Read more